Compare Davita Inc (DVA) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nuscale Power Corporation — how do they compare? Davita Inc trades at $178.07 (market cap $11.38B), while Nuscale Power Corporation trades at $9.41 (market cap $4.06B). The key difference: Davita Inc is far larger — about 2.8× Nuscale Power Corporation's market cap, and Davita Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| DVA | SMR | |
|---|---|---|
Market Cap | $11.38B | $4.06B |
Sector | Health | Utilities |
52-Week High | $240.96 | $53.43 |
52-Week Low | $103.87 | $7.59 |
Enterprise Value | $24.10B | $2.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
SMR stock trades at $9.55, up 4.03% today, with a bullish technical signal from moving averages. The company reported a net loss of $355.79M on $31.48M revenue in 2025, with negative profit margins. Recent news highlights regulatory progress for its small modular reactor technology and potential from AI data center power demand.
Outlook hinges on commercial deployment success; high risk from persistent losses and execution challenges, but Wall Street consensus price target of $10.50 suggests moderate upside. Investor sentiment is divided, with 50% of analysts rating Buy amid significant financial volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
